CARM1 Inhibition Enables Immunotherapy of Resistant Tumors by Dual Action on Tumor Cells and T Cells.

Saved in:
Bibliographic Details
Title: CARM1 Inhibition Enables Immunotherapy of Resistant Tumors by Dual Action on Tumor Cells and T Cells.
Authors: Kumar S; Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Immunology, Harvard Medical School, Boston, Massachusetts., Zeng Z; Department of Data Sciences, Dana-Farber Cancer Institute, Harvard T. H. Chan School of Public Health, Boston, Massachusetts., Bagati A; Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Immunology, Harvard Medical School, Boston, Massachusetts., Tay RE; Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Immunology, Harvard Medical School, Boston, Massachusetts., Sanz LA; Department of Molecular and Cellular Biology and Genome Center, University of California, Davis, California., Hartono SR; Department of Molecular and Cellular Biology and Genome Center, University of California, Davis, California., Ito Y; Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Immunology, Harvard Medical School, Boston, Massachusetts., Abderazzaq F; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Harvard Medical School, Boston, Massachusetts., Hatchi E; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Harvard Medical School, Boston, Massachusetts., Jiang P; Department of Data Sciences, Dana-Farber Cancer Institute, Harvard T. H. Chan School of Public Health, Boston, Massachusetts.; Center for Cancer Research, National Cancer Institute, Bethesda, Maryland., Cartwright ANR; Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Immunology, Harvard Medical School, Boston, Massachusetts., Olawoyin O; Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Yale School of Medicine, New Haven, Connecticut., Mathewson ND; Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Immunology, Harvard Medical School, Boston, Massachusetts., Pyrdol JW; Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Immunology, Harvard Medical School, Boston, Massachusetts., Li MZ; Department of Genetics, Harvard Medical School and Division of Genetics, Department of Medicine, Howard Hughes Medical Institute, Brigham and Women's Hospital, Boston, Massachusetts., Doench JG; Broad Institute of Harvard and MIT, Cambridge, Massachusetts., Booker MA; Department of Informatics and Analytics, Dana-Farber Cancer Institute, Boston, Massachusetts., Tolstorukov MY; Department of Informatics and Analytics, Dana-Farber Cancer Institute, Boston, Massachusetts., Elledge SJ; Department of Genetics, Harvard Medical School and Division of Genetics, Department of Medicine, Howard Hughes Medical Institute, Brigham and Women's Hospital, Boston, Massachusetts., Chédin F; Department of Molecular and Cellular Biology and Genome Center, University of California, Davis, California., Liu XS; Department of Data Sciences, Dana-Farber Cancer Institute, Harvard T. H. Chan School of Public Health, Boston, Massachusetts. kai_wucherpfennig@dfci.harvard.edu xsliu@ds.dfci.harvard.edu., Wucherpfennig KW; Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, Massachusetts. kai_wucherpfennig@dfci.harvard.edu xsliu@ds.dfci.harvard.edu.; Department of Immunology, Harvard Medical School, Boston, Massachusetts.; Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
Source: Cancer discovery [Cancer Discov] 2021 Aug; Vol. 11 (8), pp. 2050-2071. Date of Electronic Publication: 2021 Mar 11.
Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
Journal Info: Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 101561693 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2159-8290 (Electronic) Linking ISSN: 21598274 NLM ISO Abbreviation: Cancer Discov Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2159-8290
DOI:10.1158/2159-8290.CD-20-1144